MacroGenics (MGNX) TD Cowen 46th Annual Health Care Conference summary

Company overview and strategic direction

• Focus on next-generation antibody therapeutics for cancer, leveraging proprietary and licensed platforms such as DART, Trident, and Synaffix for bispecific, trivalent, and ADC development.

• Four wholly owned product candidates and several partnered assets, with three marketed products originating from early development efforts.

• Cash runway extended to late 2027, supported by over $600 million in non-dilutive capital raised in the past three years and ongoing corporate deal-making.

• Six key strategic imperatives set through 2026, with disciplined capital allocation and portfolio refocusing, including ending the lorigerlimab prostate study to prioritize other programs.

• Active partnerships with major pharma companies, including Gilead, Incyte, and Sanofi, providing significant potential milestone payments and diversified revenue streams.

Pipeline updates and clinical progress

• ADC pipeline includes O26 and O28 in the clinic, targeting B7H3 and ADAM9, respectively, and O30 moving toward IND filing in 2026, all leveraging Synaffix linker technology.

• Linnet study in gynecologic cancers is on partial clinical hold, with ongoing dosing for enrolled patients and active engagement with the FDA to resolve the hold.

• Lorigerlimab phase 1 showed a 26% confirmed ORR in prostate cancer, with long treatment durations and a favorable safety profile compared to traditional checkpoint inhibitors.

• MGC026 and MGC028 benefit from robust antibody and linker technology, aiming for best-in-class or first-in-class status, with competitive positioning ahead of other ADAM9-targeted ADCs.

• MGD024, partnered with Gilead, is in phase 1, with data disclosure timelines dictated by the partner.

Capital allocation, risk management, and partnership strategy

• Rigorous capital allocation process prioritizes risk assessment across platform, operational, and market risks, with ongoing portfolio pruning to focus on high-potential assets.

• Preference for partnering assets with broad development potential, while retaining focused programs for internal advancement; timing and breadth of development are key factors.

• CDMO facility generates $19–$20 million in quarterly revenue, benefiting from onshoring trends and providing an additional value lever.

• Underappreciated option value in the portfolio, with multiple clinical programs, strong partnerships, and a track record of high-value transactions.

• Active preclinical engine advances about one new IND per year, maintaining innovation and pipeline growth.